Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review

Anagrelide is used worldwide to treat essential thrombocythemia (ET) by reducing platelet counts. Cardiomyopathy and heart failure (HF) are rare but serious complications associated with anagrelide use, although no cases were reported during Japanese Phase I to III studies. A 46-year-old, otherwise...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugawara, Masafumi, Okada, Sho, Kanda, Masato, Iseki, Tohru, Sakaida, Emiko, Kobayashi, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683813/
https://www.ncbi.nlm.nih.gov/pubmed/35342135
http://dx.doi.org/10.2169/internalmedicine.9090-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683813/
https://www.ncbi.nlm.nih.gov/pubmed/35342135
http://dx.doi.org/10.2169/internalmedicine.9090-21

Ejemplares similares